April 6, 2022
GSK-Vir’s Sotrovimab No Longer Authorized to Treat COVID-19 in U.S.
FDA said that GSK’s sotrovimab is not authorized in any U.S. state or territory at this time, as CDC’s data showed the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant.